Bicycle Therapeutics reported collaboration revenue of $34.1 million for the quarter ended September 30, 2026, a significant increase from $11.7 million in the prior year. The company reduced its quarterly net loss to $9.3 million compared to $58.9 million in 2025, primarily driven by higher revenue and a decrease in research and development expenses following a strategic reprioritization.
Bicycle Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $469.9 million and a runway extending into 2030. The company also announced that the FDA granted Orphan Drug Designation to nuzefatide pevedotin for pancreatic cancer and plans to initiate its first company-sponsored radioligand clinical trial in 2H 2027.
“We are pleased with the continued progress made across our pipeline during the third quarter, as we advance nuzefatide pevedotin in the Phase 2 clinical trial in patients with recurrent pancreatic ductal adenocarcinoma and build our emerging pipeline of next-generation radioligands.”
Kevin Lee, Ph.D., Bicycle CEO
“We remain focused on disciplined execution across our prioritized programs and believe our growing clinical data continue to demonstrate the potential of Bicycle® molecules to deliver highly targeted therapies with differentiated benefit/risk profiles.”